Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.
Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...
Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...
Researchers have established that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is not superior to enalapril in the treatment of heart failure (HF) in children who have ...
Verywell Health on MSN18d
What to Know About GDMT Heart Failure MedicationMedically reviewed by Richard N. Fogoros, MDMedically reviewed by Richard N. Fogoros, MD Guideline-directed medical therapy (GDMT) for heart failure describes evidence-based therapies that ...
Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...
Read also: Biocon arm gets USFDA nod for chronic heart failure drug Sacubitril/Valsartan Medical Dialogues team had earlier reported that the USFDA had concluded a combined cGMP inspection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback